Clinical Trials

710 enrolled

Endometrial Neoplasms

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT03315364 2026-04-01

OPTIMAL

549 enrolled

Breast Neoplasms, Recurrence

NCT04498117 2026-04-01

FLORA-5

615 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05605535 2026-04-01

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

88 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04205812 2026-03-31

POD1UM-304

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04736173 2026-03-30

ARC-10

169 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05017012 2026-03-27

MK-3475A-C18

72 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

GastrointestinalGynecologic

301 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04379635 2026-03-18

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

453 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

756 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05984277 2026-03-17

eVOLVE-Lung02

1,200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05227664 2026-03-16

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

120 enrolled

Triple Negative Breast Neoplasms

NCT06332092 2026-03-16

HNSCC

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06704724 2026-03-13

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT04895358 2026-03-11

KEYNOTE-B49

340 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Ovarian Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05904379 2026-03-09

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

233 enrolled

Advanced Non-small-cell Lung Cancer

NCT06194448 2026-03-06

NEOLA

76 enrolled

Lung Neoplasms

NCT05247684 2026-03-05

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

90 enrolled

Resectable Non-small Cell Lung Cancer

NCT06018337 2026-03-05

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

541 enrolled

Breast Neoplasms

NCT06883630 2026-03-05

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

121 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 2 FDA

Breast Neoplasms

NCT06619236 2026-03-03

RAINFOL-02

530 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06727565 2026-03-02

VELOCITY-HNSCC

100 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06356311 2026-02-27

TroFuse-015

450 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

83 enrolled

Triple Negative Breast Neoplasms

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

927 enrolled

Breast Neoplasms

NCT04644068 2026-02-19

PETRA

BreastGastrointestinalGenitourinaryGynecologicThoracic

702 enrolled

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03233139 2026-02-12

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

146 enrolled

Advanced Malignancies

NCT05775289 2026-02-11

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

182 enrolled 35 charts

Carcinoma, Non-Small-Cell Lung

NCT01081951 2026-02-05

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

162 enrolled 15 charts

Ovarian Neoplasms

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

500 enrolled

Solid Cancer

NCT03742102 2026-02-02

BEGONIA

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05502237 2026-01-30

STAR-121

1,021 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03768063 2026-01-29

IMbrella B

1,000 enrolled

Tumor-Agnostic

Neoplasms

NCT05374512 2026-01-27

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

644 enrolled